Pulmonary toxicity of antineoplastic therapy.
Pulmonary toxicity is often encountered in patients receiving antineoplastic therapy. It may produce a wide variety of clinicopathologic syndromes. As new agents are introduced and their adverse effects recognized, clinicians should be ever vigilant about the possibility of pulmonary toxicity.
Kreisman
H
H
Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Wolkove
N
N
D000477:Alkylating Agents / Q000009:adverse effects; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced*; D009369:Neoplasms / Q000188:drug therapy; D009607:Nitrosourea Compounds / Q000009:adverse effects
D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D009607:Nitrosourea Compounds